HCM
SNDX icon

Hollencrest Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Hollencrest Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-232
Closed -$3.07K – 1229
2024
Q4 		$3.07K Buy
+232
New +$3.97K ﹤0.01% 955

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hollencrest Capital Management's SNDX Position: Q1 2025 in Review

Hollencrest Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2025, closing a stake of 232 shares — an estimated $3.07K sold.

Hollencrest Capital Management first reported a position in SNDX in Q4 2024 and held it in 1 quarter. The position peaked at $3.07K in Q4 2024. 218 funds tracked by Wall St. Rank hold SNDX as of Q1 2025.

  • Hollencrest Capital Management reported no remaining Syndax Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Hollencrest Capital Management sold 232 Syndax Pharmaceuticals shares in Q1 2025, an estimated $3.07K.
  • Hollencrest Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Hollencrest Capital Management's Syndax Pharmaceuticals position peaked at $3.07K in Q4 2024.
  • 218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2025.

Based on Hollencrest Capital Management's 13F filing for Q1 2025, filed 5 May 2025.